nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.03.2011 | Review

Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview

verfasst von: S. Bünger, T. Laubert, U. J. Roblick, J. K. Habermann

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Complete resection constitutes the only curative approach in pancreatic cancer but is possible only in a minority of patients due to advanced stages upon diagnosis. Consequently, early detection is crucial for curative treatment. Clinical routine still lacks efficient, non-invasive screening assays, and 80–90% of pancreatic carcinomas are detected at unresectable stages. A wide range of serum proteins have been in the focus of intensive search for biomarkers specific for pancreatic cancer. This article will give an overview on serum biomarkers with screening potential for pancreatic malignancy.

Design and methods

PUBMED database was searched for articles, and 43 manuscripts were selected that provided data regarding biomarkers used, type of assay, study population, sample cohort quality and diagnostic performance.

Results

Superior values for diagnostic performance were shown for MIC-1, PAM4, OPN, HSP27, TPS, TSGF, and CAM17.1 as individual markers. Panels of biomarkers comprised CA 19-9, MCSF, CEA, SAA, Haptoglobin, TSGF, CA 242, and HSP27. Individually or in concerted form, sensitivity and specificity ranged from 77 to 100% and 84–100%, respectively.

Conclusions

While the above named markers show high screening potential for pancreatic cancer, standardized validation studies using multiplex assays are required to pave the way for clinical routine application.

Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini P (1993) Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 39:420–423PubMed

Benson AB 3rd (2007) Adjuvant therapy for pancreatic cancer: one small step forward. JAMA 297:311–313CrossRefPubMed

Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49:1–6CrossRefPubMed

Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC et al (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29:365–371CrossRefPubMed

Brenner H, Hakulinen T (2009) Up-to-date cancer survival: period analysis and beyond. Int J Cancer 124:1384–1390CrossRefPubMed

Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K (2006) Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 141:968–973 ;(discussion 974)

Duraker N, Hot S, Polat Y, Hobek A, Gencler N, Urhan N (2007) CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 95:142–147CrossRefPubMed

Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S, Bogumil R, Buchler MW, Friess H (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34:205–214CrossRefPubMed

Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, Conrad T, Witzigmann H, Weimann A, Schutte C et al (2009) Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. Clin Cancer Res 15:3812–3819CrossRefPubMed

Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ (2009) Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg 33:716–722CrossRefPubMed

Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N, Nielsen HJ (2008) Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 23:42–47PubMed

Galasso D, Carnuccio A, Larghi A (2010) Pancreatic cancer: diagnosis and endoscopic staging. Eur Rev Med Pharmacol Sci 14:375–385

Gansauge F, Gansauge S, Parker N, Beger MI, Poch B, Link KH, Safi F, Beger HG (1996) CAM 17.1—a new diagnostic marker in pancreatic cancer. Br J Cancer 74:1997–2002CrossRefPubMed

Ghaneh P, Costello E, Neoptolemos JP (2007) Biology and management of pancreatic cancer. Gut 56:1134–1152CrossRefPubMed

Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban R, Goldenberg DM (2010) Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev

Goodwin RJ, Dungworth JC, Cobb SR, Pitt AR (2008) Time-dependent evolution of tissue markers by MALDI-MS imaging. Proteomics 8:3801–3808CrossRefPubMed

Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33:266–270CrossRefPubMed

Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, Mysliwiec P, Kedra B, Szmitkowski M (2007) Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin Chem Lab Med 45:30–34CrossRefPubMed

Haglund C, Lundin J, Kuusela P, Roberts PJ (1994) CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 70:487–492CrossRefPubMed

Holten-Andersen MN, Schrohl AS, Brunner N, Nielsen HJ, Hogdall CK, Hogdall EV (2003) Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers 18:170–176PubMed

Jiang JT, Wu CP, Deng HF, Lu MY, Wu J, Zhang HY, Sun WH, Ji M (2004a) Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol 10:1675–1677PubMed

Jiang XT, Tao HQ, Zou SC (2004b) Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 3:464–468PubMed

Joergensen MT, Brunner N, De Muckadell OB (2010) Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res 30:587–592

Katz MH, Hwang R, Fleming JB, Evans DB (2008) Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin 58:111–125CrossRefPubMed

Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH et al (2004a) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10:2386–2392CrossRefPubMed

Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ, Goggins M (2004b) Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 13:487–491PubMed

Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M (2006) Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12:442–446CrossRefPubMed

Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM (2007) Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 6:641–645PubMed

Liao WC, Wu MS, Wang HP, Tien YW, Lin JT (2009) Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas 38:422–426CrossRefPubMed

Liu RC, Traverso LW (2005) Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 19:638–642CrossRefPubMed

Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG (2009) Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? J Am Coll Surg 208:87–95CrossRefPubMed

McCarthy MJ, Evans J, Sagar G, Neoptolemos JP (1998) Prediction of resectability of pancreatic malignancy by computed tomography. Br J Surg 85:320–325CrossRefPubMed

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93:387–391CrossRefPubMed

McSweeney SE, O’Donoghue PM, Jhaveri K (2010) Current and emerging techniques in gastrointestinal imaging. J Postgrad Med 56:109–116

Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, Thieme H, Kaufmann R, Felix K, Friess HM et al (2007) Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem 53:629–635CrossRefPubMed

Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G, Szmitkowski M (2009) Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 38:613–618CrossRefPubMed

Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q et al (2005) The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31:164–169CrossRefPubMed

Nieto J, Grossbard ML, Kozuch P (2008) Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13:562–576CrossRefPubMed

Ozkan H, Akar T, Koklu S, Coban S (2006) Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases. Pancreatology 6:268–272CrossRefPubMed

Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E (1994) A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Br J Cancer 69:562–565CrossRefPubMed

Pieragostino D, Petrucci F, Del Boccio P, Mantini D, Lugaresi A, Tiberio S, Onofrj M, Gambi D, Sacchetta P, Di Ilio C et al (2010) Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. J Proteomics 73:579–592

Rosch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV Jr, Yasuda K, Heyder N, Palazzo L, Dancygier H, Schusdziarra V et al (1992) Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 326:1721–1726CrossRefPubMed

Rouy D, Ernens I, Jeanty C, Wagner DR (2005) Plasma storage at −80 degree C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem 338:294–298CrossRefPubMed

Schrohl AS, Wurtz S, Kohn E, Banks RE, Nielsen HJ, Sweep FC, Brunner N (2008) Banking of biological fluids for studies of disease-associated protein biomarkers. Mol Cell Proteomics 7:2061–2066CrossRefPubMed

Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 63:834–840CrossRefPubMed

Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, Bamberger AM, Greenson J, Brand RE, Ramachandran V et al (2007) CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34:436–443CrossRefPubMed

Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615CrossRefPubMed

Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, Yatabe Y, Matsuo K, Uehara R, Ono K et al (2010) Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol 45:52–59CrossRefPubMed

Taylor CF, Paton NW, Lilley KS, Binz PA, Julian RK Jr, Jones AR, Zhu W, Apweiler R, Aebersold R, Deutsch EW et al (2007) The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol 25:887–893CrossRefPubMed

Thurigen D, Spiegelman D, Blettner M, Heuer C, Brenner H (2000) Measurement error correction using validation data: a review of methods and their applicability in case–control studies. Stat Methods Med Res 9:447–474CrossRefPubMed

Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L (2004) Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 49:1149–1155CrossRefPubMed

Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ (2006) Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis 7:170–174CrossRefPubMed

Yiannakou JY, Newland P, Calder F, Kingsnorth AN, Rhodes JM (1997) Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 349:389–392CrossRefPubMed

Zhao YP, Zhang TP (2008) Present status of and prospects for basic research on pancreatic cancer. Zhonghua Yi Xue Za Zhi 88:1945–1947PubMed

Titel: Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview
verfasst von: S. Bünger
T. Laubert
U. J. Roblick
J. K. Habermann
Publikationsdatum: 01.03.2011
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0965-x

Springer Medizin

Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview

Abstract

Purpose

Design and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Design and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Overexpression of T lymphoma invasion and metastasis 1 predict renal cell carcinoma metastasis and overall patient survival

Influence of TGFB1+869T>C functional polymorphism in non-small cell lung cancer (NSCLC) risk

Characterization of human multicentric osteosarcoma using newly established cells derived from multicentric osteosarcoma

Overexpression of SUMO-1 in hepatocellular carcinoma: a latent target for diagnosis and therapy of hepatoma

Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol

L-methionine-induced alterations in molecular signatures in MCF-7 and LNCaP cancer cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie